Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma

Abstract While there are various attempts to administer COVID-19-convalescent plasmas to SARS-CoV-2-infected patients, neither appropriate approach nor clinical utility has been established. We examined the presence and temporal changes of the neutralizing activity of IgG fractions from 43 COVID-19-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kenji Maeda, Nobuyo Higashi-Kuwata, Noriko Kinoshita, Satoshi Kutsuna, Kiyoto Tsuchiya, Shin-ichiro Hattori, Kouki Matsuda, Yuki Takamatsu, Hiroyuki Gatanaga, Shinichi Oka, Haruhito Sugiyama, Norio Ohmagari, Hiroaki Mitsuya
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/970cba33ead34dc8a53bb58f6d2d522f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:970cba33ead34dc8a53bb58f6d2d522f
record_format	dspace
spelling	oai:doaj.org-article:970cba33ead34dc8a53bb58f6d2d522f2021-12-02T15:54:03ZNeutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma10.1038/s41598-021-84733-52045-2322https://doaj.org/article/970cba33ead34dc8a53bb58f6d2d522f2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84733-5https://doaj.org/toc/2045-2322Abstract While there are various attempts to administer COVID-19-convalescent plasmas to SARS-CoV-2-infected patients, neither appropriate approach nor clinical utility has been established. We examined the presence and temporal changes of the neutralizing activity of IgG fractions from 43 COVID-19-convalescent plasmas using cell-based assays with multiple endpoints. IgG fractions from 27 cases (62.8%) had significant neutralizing activity and moderately to potently inhibited SARS-CoV-2 infection in cell-based assays; however, no detectable neutralizing activity was found in 16 cases (37.2%). Approximately half of the patients (~ 41%), who had significant neutralizing activity, lost the neutralization activity within ~ 1 month. Despite the rapid decline of neutralizing activity in plasmas, good amounts of SARS-CoV-2-S1-binding antibodies were persistently seen. The longer exposure of COVID-19 patients to greater amounts of SARS-CoV-2 elicits potent immune response to SARS-CoV-2, producing greater neutralization activity and SARS-CoV-2-S1-binding antibody amounts. The dilution of highly-neutralizing plasmas with poorly-neutralizing plasmas relatively readily reduced neutralizing activity. The presence of good amounts of SARS-CoV-2-S1-binding antibodies does not serve as a surrogate ensuring the presence of good neutralizing activity. In selecting good COVID-19-convalescent plasmas, quantification of neutralizing activity in each plasma sample before collection and use is required.Kenji MaedaNobuyo Higashi-KuwataNoriko KinoshitaSatoshi KutsunaKiyoto TsuchiyaShin-ichiro HattoriKouki MatsudaYuki TakamatsuHiroyuki GatanagaShinichi OkaHaruhito SugiyamaNorio OhmagariHiroaki MitsuyaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kenji Maeda Nobuyo Higashi-Kuwata Noriko Kinoshita Satoshi Kutsuna Kiyoto Tsuchiya Shin-ichiro Hattori Kouki Matsuda Yuki Takamatsu Hiroyuki Gatanaga Shinichi Oka Haruhito Sugiyama Norio Ohmagari Hiroaki Mitsuya Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
description	Abstract While there are various attempts to administer COVID-19-convalescent plasmas to SARS-CoV-2-infected patients, neither appropriate approach nor clinical utility has been established. We examined the presence and temporal changes of the neutralizing activity of IgG fractions from 43 COVID-19-convalescent plasmas using cell-based assays with multiple endpoints. IgG fractions from 27 cases (62.8%) had significant neutralizing activity and moderately to potently inhibited SARS-CoV-2 infection in cell-based assays; however, no detectable neutralizing activity was found in 16 cases (37.2%). Approximately half of the patients (~ 41%), who had significant neutralizing activity, lost the neutralization activity within ~ 1 month. Despite the rapid decline of neutralizing activity in plasmas, good amounts of SARS-CoV-2-S1-binding antibodies were persistently seen. The longer exposure of COVID-19 patients to greater amounts of SARS-CoV-2 elicits potent immune response to SARS-CoV-2, producing greater neutralization activity and SARS-CoV-2-S1-binding antibody amounts. The dilution of highly-neutralizing plasmas with poorly-neutralizing plasmas relatively readily reduced neutralizing activity. The presence of good amounts of SARS-CoV-2-S1-binding antibodies does not serve as a surrogate ensuring the presence of good neutralizing activity. In selecting good COVID-19-convalescent plasmas, quantification of neutralizing activity in each plasma sample before collection and use is required.
format	article
author	Kenji Maeda Nobuyo Higashi-Kuwata Noriko Kinoshita Satoshi Kutsuna Kiyoto Tsuchiya Shin-ichiro Hattori Kouki Matsuda Yuki Takamatsu Hiroyuki Gatanaga Shinichi Oka Haruhito Sugiyama Norio Ohmagari Hiroaki Mitsuya
author_facet	Kenji Maeda Nobuyo Higashi-Kuwata Noriko Kinoshita Satoshi Kutsuna Kiyoto Tsuchiya Shin-ichiro Hattori Kouki Matsuda Yuki Takamatsu Hiroyuki Gatanaga Shinichi Oka Haruhito Sugiyama Norio Ohmagari Hiroaki Mitsuya
author_sort	Kenji Maeda
title	Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
title_short	Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
title_full	Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
title_fullStr	Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
title_full_unstemmed	Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
title_sort	neutralization of sars-cov-2 with igg from covid-19-convalescent plasma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/970cba33ead34dc8a53bb58f6d2d522f
work_keys_str_mv	AT kenjimaeda neutralizationofsarscov2withiggfromcovid19convalescentplasma AT nobuyohigashikuwata neutralizationofsarscov2withiggfromcovid19convalescentplasma AT norikokinoshita neutralizationofsarscov2withiggfromcovid19convalescentplasma AT satoshikutsuna neutralizationofsarscov2withiggfromcovid19convalescentplasma AT kiyototsuchiya neutralizationofsarscov2withiggfromcovid19convalescentplasma AT shinichirohattori neutralizationofsarscov2withiggfromcovid19convalescentplasma AT koukimatsuda neutralizationofsarscov2withiggfromcovid19convalescentplasma AT yukitakamatsu neutralizationofsarscov2withiggfromcovid19convalescentplasma AT hiroyukigatanaga neutralizationofsarscov2withiggfromcovid19convalescentplasma AT shinichioka neutralizationofsarscov2withiggfromcovid19convalescentplasma AT haruhitosugiyama neutralizationofsarscov2withiggfromcovid19convalescentplasma AT norioohmagari neutralizationofsarscov2withiggfromcovid19convalescentplasma AT hiroakimitsuya neutralizationofsarscov2withiggfromcovid19convalescentplasma
_version_	1718385464041275392

Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma

Ejemplares similares